MedTrace Logo

Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder

NCT01158001 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2015-06-24

No results posted yet for this study

Summary

The objective of the proposed study is to conduct a systematic comparison of post traumatic stress disorder (PTSD) outcomes for veterans receiving exposure therapy via telemedicine versus in-person care. The primary aim is to determine feasibility: whether telemedicine can be used as a tool to extend effective, specialized mental health services, such as Prolonged Exposure therapy (PE; a therapy designed to help clients face fears related to a traumatic event), to veterans with limited access to care. A secondary aim is to determine if therapy delivered by telemedicine affects the quality of care in terms of clinical outcomes and the quality of patient-therapist interaction. A tertiary aim is to examine whether results from neuropsychological testing predict treatment outcomes.

Conditions

Interventions

BEHAVIORAL

Prolonged exposure therapy

Twelve sessions (90 minutes each) of prolonged exposure therapy

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Pennsylvania

    collaborator OTHER

  • Veterans Medical Research Foundation

    lead OTHER

Principal Investigators

  • Steven R. Thorp, PhD · Veterans Affairs San Diego Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-06-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01158001 on ClinicalTrials.gov